FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment

Trial details

Who runs it

Karolinska University Hospital

Trial code

EU 2026-526961-76-00

Record updated

2026. július 14.

Original description

Phase I (run-in): To assess the safety and tolerability of HU at two different dose-levels added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax (frequency and severity of adverse events and dose-limiting toxicities; dose-finding). Phase II: To assess the impact of HU added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax on the 1-year event-free survival (EFS) defined as from the time from initiation of study treatment to the first occurrence of treatment failure, hematologic relapse from CR/CRi, or death from any cause.Read full original descriptionShow less

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

Phase I (run-in): To assess the safety and tolerability of HU at two different dose-levels added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax (frequency and severity of adverse events and dose-limiting toxicities; dose-finding). Phase II: To assess the impact of HU added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax on the 1-year event-free survival (EFS) defined as from the time from initiation of study treatment to the first occurrence of treatment failure, hematologic relapse from CR/CRi, or death from any cause.

Inclusion: A diagnosis of either: • Refractory AML defined as having > 10% bone marrow blasts after induction with one cycle of intensive chemotherapy or no CR after two cycles of chemotherapy. • Relapsed disease (including extramedullary disease) according to the 2022 ELN criteria (see appendix A). • MRD relapse defined as evidence of measurable (minimal) residual disease (MRD) at a level of ≥5%, as determined by either validated genetic assays or multiparameter flow cytometry; The subject has given their written consent to participate in the trial; Patient is capable of giving informed consent; Age 18 years or older; ECOG Performance Status ≤ 2; Adequate renal and hepatic functions as indicated by the following laboratory values: - Creatinine clearance ≥ 30 mL/min calculated by the Cockcroft Gault formula. - Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless due to Gilbert’s syndrome. - Alanine aminotransferase (ALAT) ≤ 5 x ULN; Considered fit for intensive chemotherapy; Male patients must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid fathering a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control; Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration; Female patients of nonchildbearing potential must be postmenopausal (defined as at least 1 year without any menses), documented surgically sterile prior to screening; Female patients of childbearing potential must agree to avoid pregnancy during the study and for 6 months after the final study drug administration and have a negative urine or serum pregnancy test at screening, and if heterosexually active, agree to consistently apply one highly effective method of birth control in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration.

Exclusion: Known intolerance to any of the chemotherapeutic drugs in the protocol; Known inherited bone marrow failure syndromes (e.g., Fanconi anemia, Dyskeratosis congenita and related telomeropathies (e.g., TERT, TERC, DKC1 mutations); Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance; Uncontrolled infection; Major organ failure precluding administration of planned chemotherapy; WBC ≥30; pretreatment with HU to reduce the level of WBC <30 is allowed in part B/phase II of the trial; Cardiac dysfunction as defined by: o Myocardial infarction within the last 3 months of study entry, or o Reduced left ventricular function with an ejection fraction < 50% as measured by echocardiogram (will only be performed when clinically suspected) or o Unstable angina or o New York Heart Association (NYHA) grade III or IV congestive heart failure (see appendix C) or o Severe cardiac arrhythmias; Age 75 years or older; Acute promyelocytic leukemia; Positive pregnancy test; Lactating female or female of childbearing potential not using adequate contraception; TP53 double hit mutation / biallelic TP53 inactivation; CNS leukemia; Relapse within 3 months from the date of allo-HCT; ECOG Performance Status > 2.

EU CTIS 2026-526961-76-00